BioNTech SE (NASDAQ:BNTX - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $103.56, but opened at $99.89. BioNTech shares last traded at $97.91, with a volume of 505,019 shares.
Analysts Set New Price Targets
Several research firms have recently issued reports on BNTX. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday. The Goldman Sachs Group upgraded BioNTech from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Deutsche Bank Aktiengesellschaft increased their price target on shares of BioNTech from $95.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, September 19th. UBS Group lifted their price objective on shares of BioNTech from $97.00 to $131.00 and gave the stock a "neutral" rating in a research report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $125.00 to $124.00 and set a "neutral" rating for the company in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $137.54.
Check Out Our Latest Stock Analysis on BNTX
BioNTech Price Performance
The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business's 50-day simple moving average is $113.54 and its 200-day simple moving average is $97.18. The stock has a market cap of $23.91 billion, a PE ratio of -47.49 and a beta of 0.26.
BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 earnings per share. On average, research analysts expect that BioNTech SE will post -3.47 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in BNTX. FMR LLC grew its holdings in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the period. Fred Alger Management LLC bought a new position in BioNTech in the 3rd quarter worth about $59,485,000. Candriam S.C.A. increased its stake in BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock valued at $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock worth $37,103,000 after buying an additional 341,311 shares during the last quarter. Finally, Braidwell LP bought a new stake in shares of BioNTech during the third quarter valued at approximately $29,425,000. Hedge funds and other institutional investors own 15.52% of the company's stock.
About BioNTech
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Stories
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
